Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties.

Autor:	Figuera-Losada M; Brain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Stathis M; Brain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Dorskind JM; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Thomas AG; Brain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Bandaru VV; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Yoo SW; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Westwood NJ; School of Chemistry and Biomedical Sciences Research Centre, University of Saint Andrews and EaStCHEM, North Haugh, Saint Andrews, Fife, KY16 9ST, United Kingdom., Rogers GW; School of Chemistry and Biomedical Sciences Research Centre, University of Saint Andrews and EaStCHEM, North Haugh, Saint Andrews, Fife, KY16 9ST, United Kingdom., McArthur JC; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Haughey NJ; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Richard T. Johnson Division of Neuroimmunology and Neurological Infections, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Slusher BS; Brain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Rojas C; Brain Science Institute Drug Discovery Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Jazyk:	angličtina
Zdroj:	PloS one [PLoS One] 2015 May 26; Vol. 10 (5), pp. e0124481. Date of Electronic Publication: 2015 May 26 (Print Publication: 2015).
DOI:	10.1371/journal.pone.0124481
Abstrakt:	Ceramide is a bioactive lipid that plays an important role in stress responses leading to apoptosis, cell growth arrest and differentiation. Ceramide production is due in part to sphingomyelin hydrolysis by sphingomyelinases. In brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increases in its activity and expression have been associated with pro-inflammatory conditions observed in Alzheimer's disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Increased nSMase2 activity translates into higher ceramide levels and neuronal cell death, which can be prevented by chemical or genetic inhibition of nSMase2 activity or expression. However, to date, there are no soluble, specific and potent small molecule inhibitor tool compounds for in vivo studies or as a starting point for medicinal chemistry optimization. Moreover, the majority of the known inhibitors were identified using bacterial, bovine or rat nSMase2. In an attempt to identify new inhibitor scaffolds, two activity assays were optimized as screening platform using the recombinant human enzyme. First, active hits were identified using a fluorescence-based high throughput compatible assay. Then, hits were confirmed using a 14C sphingomyelin-based direct activity assay. Pharmacologically active compounds and approved drugs were screened using this strategy which led to the identification of cambinol as a novel uncompetitive nSMase2 inhibitor (Ki = 7 μM). The inhibitory activity of cambinol for nSMase2 was approximately 10-fold more potent than for its previously known target, silence information regulator 1 and 2 (SIRT1/2). Cambinol decreased tumor necrosis factor-α or interleukin-1 β-induced increases of ceramide and cell death in primary neurons. A preliminary study of cambinol structure and activity allowed the identification of the main structural features required for nSMase2 inhibition. Cambinol and its analogs may be useful as nSMase2 inhibitor tool compounds to prevent ceramide-dependent neurodegeneration.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF